TICKERNERD
Menu
AQSTAQSTHealthcare · Drug Manufacturers - Specialty & Generic

AQST Stock Forecast: Aquestive Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 7 Oct 2026
$4.61
0.00% on the day

The 9 Wall Street analysts covering Aquestive Therapeutics, Inc. hold a median 12-month price target of $10 — +116.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 53 of 100 as at 6 Oct 2026 — in the upper half.

Market cap
$578.6M
Ticker Nerd rank
53 / 100
Median analyst target
$10
Analysts covering
9
Revenue$13.8M+38.1% y/y
Operating income−$8.2M
Net income−$22.9M
Free cash flow−$9.7M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−0.4%
1M
−13.7%
YTD
−28.6%
1Y
−22.8%
From 52W high
−38.5%
From 52W low
+56.3%
$2.95
$7.49
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

AQST stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Aquestive Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 6 Oct 2026
53 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
90
Accruals
68
Volatility
67
Momentum
57
Value
57
Size
51
Quality
50
Revisions
42
Issuance
9

Growth (90): Sales and profits are climbing, and climbing faster than before.

Issuance (9): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

AQST stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on AQST, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2.00$4.00$6.00$8.00$10.00$12.00Jan 26Apr 26Jul 26Oct 26AQSTHigh $11Median $10Low $6

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says9 analysts
9 Buy0 Hold0 Sell
Low $6Median $10High $11

The green dot is the last close — the median target sits +116.9% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
24 Aug 2026HC Wainwright & Co.ReiteratesBuy$10
7 Nov 2025Piper SandlerMaintainsOverweight—
7 Nov 2025Piper SandlerMaintainsOverweight$5.00 → $8.00
9 Oct 2025JMP SecuritiesMaintainsMarket Outperform—
8 Sept 2025OppenheimerMaintainsOutperform—
17 June 2025HC Wainwright & Co.ReiteratesBuy—
2 June 2025OppenheimerAssumesOutperform$15 → $7.00
15 May 2025HC Wainwright & Co.ReiteratesBuy—
2 Apr 2025HC Wainwright & Co.ReiteratesBuy—
10 Mar 2025HC Wainwright & Co.ReiteratesBuy—
7 Mar 2025Lake StreetMaintainsBuy—
20 Dec 2024HC Wainwright & Co.ReiteratesBuy—
17 Dec 2024Cantor FitzgeraldInitiatesOverweight—
11 Nov 2024HC Wainwright & Co.ReiteratesBuy—
6 Nov 2024HC Wainwright & Co.ReiteratesBuy—
25 Oct 2024HC Wainwright & Co.ReiteratesBuy—
25 Oct 2024Leerink PartnersMaintainsOutperform—
8 Oct 2024JMP SecuritiesReiteratesMarket Outperform—
30 Sept 2024HC Wainwright & Co.MaintainsBuy—
30 Sept 2024JMP SecuritiesReiteratesMarket Outperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AQST appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

AQST vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 7 Oct 2026, Aquestive Therapeutics, Inc. returned −22.8% against +17.7% for the S&P 500, dividends included.

AQST vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120Jan 26Apr 26Jul 26Oct 26AQSTS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

AQST analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
1
Fundamentals

Aquestive Therapeutics, Inc. (AQST) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−5.9×

Cheaper than 91% of US stocks

Price / sales
10.7×

Cheaper than 14% of US stocks

Price / book
−10.2×

Cheaper than 97% of US stocks

EV / EBITDA
−10.3×

Cheaper than 85% of US stocks

Growth & margins
Revenue growth (YoY)
38.1%

Higher than 82% of US stocks

Earnings growth (YoY)
38.1%

Higher than 70% of US stocks

Gross margin
70.9%

Higher than 83% of US stocks

Operating margin
−59.5%

Higher than 16% of US stocks

Net margin
−144.6%

Higher than 4% of US stocks

Returns & dividend
Return on equity
248.9%

Higher than 99% of US stocks

Return on assets
−29.2%

Higher than 14% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Aquestive Therapeutics, Inc. (AQST) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Aquestive Therapeutics, Inc. has a market value of $578.6M and an enterprise value of $539.1M.

  • Revenue in the twelve months to 30 June 2026: $54.1M. The latest quarter grew 38.1% year on year.

  • Net income over the same four quarters: −$78.2M, a −144.6% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.65.

  • Free cash flow in the twelve months to 30 June 2026: −$45.9M, after $584K of capital spending.

  • Shares outstanding: 125.5M.

  • Trailing P/E: −5.9×; forward P/E: −8.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Aquestive Therapeutics, Inc. employs 147 people — $368K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 7 Oct 2026

Data provided by Twelve Data

Peers

AQST vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
AQSTAquestive Therapeutics, Inc.$578.6M
53
IRWDIronwood Pharmaceuticals, Inc.$591.9M
100
TLRYTilray Brands, Inc.$558.6M
14
COLLCollegium Pharmaceutical, Inc.$691.6M
70
EOLSEvolus, Inc.$480.1M
89
KMDAKamada Ltd.$475.7M
93
TKNOAlpha Teknova, Inc.$469.1M
96

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Aquestive Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest AQST news & analysis

Aquestive Therapeutics, Inc. (Nasdaq: AQST) Investor Alert: Schubert Jonckheer Investigating Possible False Statements Following 37% Stock Drop

PRNewsWire · 7 Oct 2026negative

Schubert Jonckheer & Kolbe LLP said it is investigating potential legal claims alleging false or misleading statements about Aquestive Therapeutics’ drug candidate Anaphylm. The firm invited current shareholders to contact it.

Why it matters — The investigation concerns alleged company statements about Anaphylm, an issue relevant to AQST shareholders.

Aquestive Therapeutics Strengthens Board of Directors with Appointment of Richard Daly

GlobeNewsWire · 29 Sept 2026positive

Aquestive Therapeutics announced the appointment of Rich Daly, a life sciences executive with more than 30 years of leadership experience across large pharmaceutical companies, emerging biotechnology companies, and public company boards, to its Board of Directors, effective October 14, 2026.

Why it matters — The addition of an experienced life sciences executive to the board strengthens the company's leadership and governance as it advances its pharmaceutical pipeline.

Aquestive Therapeutics Announces Resubmission of New Drug Application to FDA for Anaphylm™ (dibutepinephrine) Sublingual Film

GlobeNewsWire · 17 Sept 2026positive

Aquestive Therapeutics announced it has resubmitted its New Drug Application to the U.S. FDA for Anaphylm (dibutepinephrine) sublingual film, intended to treat Type I allergic reactions including anaphylaxis. The resubmission is supported by positive topline human factors and pharmacokinetic study results announced in August 2026, and the FDA will determine the resubmission classification and applicable review timeline.

Why it matters — The resubmission, backed by positive study results, moves Aquestive's lead candidate Anaphylm a step closer to a potential FDA review and approval decision.

Aquestive Therapeutics to Participate in Upcoming September Investor Conferences

GlobeNewsWire · 1 Sept 2026neutral

Aquestive Therapeutics announced that its management team will participate in four investor conferences scheduled for September 2026. The company, which develops medicines through innovative delivery technologies, said its team will attend these upcoming events per an announcement on September 1, 2026.

Why it matters — The conference appearances give Aquestive watchers opportunities to hear management present updates on the company at investor events during September.

Aquestive Therapeutics, Inc. (AQST) Q2 2026 Earnings Call Transcript

Seeking Alpha · 12 Aug 2026neutral

Aquestive Therapeutics, Inc. (AQST) held its Q2 2026 earnings call, with a transcript of the call published by Seeking Alpha. The item reports the occurrence of the company's second-quarter 2026 earnings call.

Why it matters — An AQST watcher would turn to this transcript for management's commentary on the company's quarterly results and outlook.

FAQ

Frequently asked questions about AQST stock

What is the AQST stock price forecast for 2026-2027?

The 9 Wall Street analysts covering Aquestive Therapeutics, Inc. have a median 12-month price target of $10, with estimates ranging from $6 to $11. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is AQST stock a buy right now?

Of the 9 analysts covering Aquestive Therapeutics, Inc., 9 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Aquestive Therapeutics, Inc. 53 out of 100 across roughly 4,600 US stocks as at 6 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank AQST?

As at 6 Oct 2026, Aquestive Therapeutics, Inc. ranks 53 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (90 of 100).

Will AQST stock go up?

No one can know that. What the data says: the median 12-month target from 9 analysts implies +116.9% from the last close, and Ticker Nerd's factor model ranks Aquestive Therapeutics, Inc. 53 out of 100 as at 6 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the AQST stock forecast for 2030?

No analyst covering Aquestive Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AQST are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $11 over the next 12 months.

How has AQST stock performed over the past year?

Aquestive Therapeutics, Inc. returned -22.8% over the 12 months to 7 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Aquestive Therapeutics, Inc. do?

Aquestive Therapeutics Inc. is a specialty pharmaceutical company focused on developing and commercializing oral and non-invasive drug-delivery therapies.

What is the latest news on AQST?

The most recent item we track (PRNewsWire, 7 Oct 2026): "Aquestive Therapeutics, Inc. (Nasdaq: AQST) Investor Alert: Schubert Jonckheer Investigating Possible False Statements Following 37% Stock Drop". Schubert Jonckheer & Kolbe LLP said it is investigating potential legal claims alleging false or misleading statements about Aquestive Therapeutics’ drug candidate Anaphylm. The firm invited current shareholders to contact it.

Company

About Aquestive Therapeutics, Inc.

Aquestive Therapeutics Inc. is a specialty pharmaceutical company focused on developing and commercializing oral and non-invasive drug-delivery therapies. The company’s portfolio includes approved products such as Libervant for seizure clusters, along with licensed medicines delivered through its proprietary PharmFilm technology. This platform is designed to simplify administration of complex treatments using thin-film formulations that dissolve in the mouth, supporting use cases where traditional pills, injections, or infusions may be less practical. Aquestive Therapeutics also operates as a contract development and manufacturing partner, producing and packaging pharmaceutical products for licensees and customers. Its business is centered on central nervous system therapies, emergency allergy treatments, and other conditions where alternative delivery methods can improve usability and access to care. Headquartered in Warren, New Jersey, Aquestive Therapeutics plays a niche role in the broader pharmaceutical market through differentiated formulation science and specialized manufacturing capabilities.

CEO Mr. Daniel Barber · 147 employees · United States · https://www.aquestive.com